Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

(1999): Ellenberg SS, Center for Biologics Evaluation & Research,
FDA Statement (2 cases)
(1996): Shlyakhov E+, Med Trop (Mars) 56(2), 148
(1996): Uhr JW, Physiol Rev. 46:359
(1994): Shlyakhov E+, Med Trop (Mars) 54(1):33
Injection-site burning
(1999): Dr. Sue Bailey, Asst Sec Defense Health Affairs – Service
Member #12,27
Injection-site edema
(2000): MMWR 49(RR15), 1
(1999): Dr. Sue Bailey, Asst Sec Defense Health Affairs – Service
Member #4, 12, 32
(1999): Ellenberg SS, Center for Biologics Evaluation & Research,
FDA Statement
Injection-site erythema
(1999): Dr. Sue Bailey, Asst Sec Defense Health Affairs – Service
Member #21, 27, 47
Injection-site hematoma
(1999): Dr. Sue Bailey, Asst Sec Defense Health Affairs – Service
Member #12
Injection-site hypersensitivity
(2000): MMWR 49(RR15), 1
Injection-site induration
Injection-site inflammation
Injection-site nodules
(2006): Vasudev M+, Ann Allergy Asthma Immunol 97(1), 110
(1999): Dr. Sue Bailey, Asst Sec Defense Health Affairs – Service
Members #2, 24, 28, 37, 40, 47
Injection-site numbness
(1999): Dr. Sue Bailey, Asst Sec Defense Health Affairs – Service
Members #6, 13, 15, 22, 26, 31, 39, 43
Injection-site pain
(2001): Swanson-Biearman B+, J Toxicol Clin Toxicol 39(1), 81
(2000): MMWR 49(RR15), 1
(1999): Bailey S MD, Asst Sec Defense Health Affairs – Service
Members #1, 4, 8, 13, 18, 19, 20, 42, 45, 47, 49
Injection-site pruritus
Injection-site reactions (sic)
(2001): Swanson-Biearman B+, J Toxicol Clin Toxicol 39(1), 81
(30%)
(2000): MMWR 49(RR15), 1
(2000): Hayes SC+, JRArmyMedCorps146(3), 191 (47%)
(1999): Ellenberg SS, Center for Biologics Evaluation & Research,
FDA Statement (severe)
Myalgia/Myositis/Myopathy/Myotoxicity
(2006): Vasudev M+, Ann Allergy Asthma Immunol 97(1), 110
(2000): MMWR 49(RR15), 1
(1999): Dr. Sue Bailey, Asst Sec Defense Health Affairs – Service
Members #1, 6, 12, 22, 40, 41
Pain
(2006): Vasudev M+, Ann Allergy Asthma Immunol 97(1), 110
(joint)
Systemic reactions (sic)
(2000): Hayes SC+, JRArmyMedCorps146(3), 191 (47%)
Note: Dr. Sue Bailey, Assistant Secretary for Health Affairs, released
a statement on June 29, 1999 that ‘almost one million shots given, the
anthrax immunization is proving to be one of the safest vaccination
programs on record.’ The above reports occurred for ‘50 service
members at one installation alone.’ Note that no number of military
personnel was mentioned at this installation, nor did it give any
percentages of the above reaction patterns
APOMORPHINE
Trade names: Apokyn; Uprima (Abbott)
Indications: Parkinsonism, Erectile dysfunction
Category: Dopamine receptor agonist
Half-life: 40 minutes
Clinically important, potentially hazardous interactions
with: alcohol, antihypertensives, vasodilators
Reactions
Skin
Dermatitis
(1997): Carboni GP+, Contact Dermatitis 36(3), 177
Diaphoresis
(2002): Prescrire Int 11(59), 76 (severe)
Nodular eruption
(2004): Bowron A, Neurology 62(6), S32
Peripheral edema (10%)
Pigmentation
(2003): Loewe R+, Hautarzt 54(1), 58
Other
Injection-site reactions (sic)
(2001): Dewey RB+, Arch Neurol 58(9), 1385
(1998): Pietz K+, J Neurol Neurosurg Psychiatry 65(5), 709
Panniculitis
(1998): Acland KM+, Br J Dermatol 138(3), 480
(1998): Acland KM+, Hosp Med 59(5), 413
Note: Apomorphine contains sodium metabisulfite which is capable
of causing anaphylactoid reactions in patients with sulfite allergy
APRACLONIDINE
Trade name: Iopidine (Alcon)
Indications: Post-surgical intraocular pressure elevation
Category: Adrenergic alpha2-receptor agonist
Half-life: 8 hours
Reactions
APRACLONIDINE 39
Skin
Allergic reactions (sic) (